A new drug called ceritinib may be effective against advanced ALK-positive non-small cell lung cancer (NSCLC), according to recent study reported in New England Journal of Medicine.
NSCLC is the leading cause of cancer death in the U.S., and around five percent of cases involve mutations in the ALK gene, which lead to uncontrolled tumor growth. The current Massachusetts General Hospital study was designed to measure the safety and tolerability of ceritinib in human patients. Ceritinib could be as much as 20 times stronger than crizotinib, which is the standard treatment agent. Researchers found similar results for both drugs.